Measurement of in Vivo Mitochondrial Capacity in Infants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03976596
Recruitment Status :
(Study temporarily paused due to COVID-19 and expected to resume. This is not a suspension of IRB approval.)
First Posted : June 6, 2019
Last Update Posted : May 4, 2020
Pennington Biomedical Research Center
Information provided by (Responsible Party):
Leanne Redman, Pennington Biomedical Research Center
The overarching aim of this project is to determine the test re-test reliability of 31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess feasibility and reliability.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 28 Days (Child)
Sexes Eligible for Study:
This cross-sectional study will enroll up to 18 infants. Infants will complete 2 study visits over a 1-10 day period for outcome measures.
healthy, full-term infant
aged 14-28 days at Visit 1
willingness of parents to be notified of incidental findings from study procedures
implanted metal or electronic objects that render MRI unsafe
unable to complete 2 clinic visits 1-10 days apart at Pennington Biomedical Research Center